Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives $8.00 Average Target Price from Analysts

Posted by Brian Himes on Jul 27th, 2026

Adagene Inc. Sponsored ADR (NASDAQ:ADAG – Get Free Report) has earned an average recommendation of “Buy” from the five ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $8.00.

A number of equities research analysts have issued reports on the company. Guggenheim reiterated a “buy” rating and issued a $10.00 price target on shares of Adagene in a research note on Tuesday, July 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adagene in a research report on Friday, July 17th.

Read Our Latest Report on Adagene

Institutional Investors Weigh In On Adagene

Several institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new stake in Adagene in the 1st quarter worth $135,000. Fifth Lane Capital LP raised its stake in Adagene by 427.3% during the fourth quarter. Fifth Lane Capital LP now owns 145,000 shares of the company’s stock valued at $274,000 after purchasing an additional 117,500 shares in the last quarter. Exome Asset Management LLC purchased a new stake in Adagene during the fourth quarter valued at $2,004,000. SmartHarvest Portfolios LLC bought a new position in Adagene during the fourth quarter valued at $73,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Adagene during the 3rd quarter valued at about $80,000. Institutional investors own 9.51% of the company’s stock.

Adagene Price Performance

Shares of NASDAQ:ADAG opened at $3.20 on Friday. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.03. Adagene has a 12-month low of $1.30 and a 12-month high of $4.85. The stock has a 50 day moving average of $3.76 and a 200 day moving average of $3.41.

Adagene Company Profile

(Get Free Report)

Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.